Pfizer’s Selzentry HIV Drug Faces India Opposition As Too Expensive (India)
This article was originally published in PharmAsia News
Executive Summary
Patient groups and two organizations are challenging the patent India gave to Pfizer for its Selzentry (maraviroc), one of a new class of oral AIDS drugs intended as second-line treatments. Medicines Sans frontiers and a Mumbai lawyer group are poring over the patent grant to see if it was justified, with an eye to questions raised about the drug by Europe's patent office. Challengers have a year from last June to mount an official challenge to granting a patent right. The U.S. FDA approved the drug in August. (Click here for more
You may also be interested in...
WHO Examines Ethical Criteria For Human Challenge Trials Ahead Of Next Health Emergency
The World Health Organization is looking to finalize its guidance on the ethical criteria that should be applied to studies that involve deliberately infecting healthy individuals to speed up research.
Irish Body Sets Out Five-Year Vision Strategy For Off-Patent Sector
With a focus on drug accessibility, supply chain resilience, and a balanced approach to sustainability, Medicines for Ireland “calls to action” with its five-year plan.
Post-Brexit UK Risks Being ‘Left Out In The Cold’ As EU Coordinates Action On Shortages
The UK is not alone in experiencing drug shortages, as data from across Europe show, but its departure from the EU makes it more difficult to respond to supply chain pressures, according to new research.